CN116096239B - 治疗和预防生物膜的联合疗法 - Google Patents

治疗和预防生物膜的联合疗法

Info

Publication number
CN116096239B
CN116096239B CN202180054037.0A CN202180054037A CN116096239B CN 116096239 B CN116096239 B CN 116096239B CN 202180054037 A CN202180054037 A CN 202180054037A CN 116096239 B CN116096239 B CN 116096239B
Authority
CN
China
Prior art keywords
seq
polypeptide
antibody
box
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180054037.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN116096239A (zh
Inventor
史蒂文·D·古德曼
劳伦·O·巴卡莱茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nationwide Children's Hospital
Original Assignee
Nationwide Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Children's Hospital filed Critical Nationwide Children's Hospital
Publication of CN116096239A publication Critical patent/CN116096239A/zh
Application granted granted Critical
Publication of CN116096239B publication Critical patent/CN116096239B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180054037.0A 2020-07-07 2021-07-06 治疗和预防生物膜的联合疗法 Active CN116096239B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063049065P 2020-07-07 2020-07-07
US63/049,065 2020-07-07
US202163175487P 2021-04-15 2021-04-15
US63/175,487 2021-04-15
PCT/US2021/040576 WO2022010942A2 (en) 2020-07-07 2021-07-06 Combination therapies for the treatment and prevention of biofilms

Publications (2)

Publication Number Publication Date
CN116096239A CN116096239A (zh) 2023-05-09
CN116096239B true CN116096239B (zh) 2025-09-02

Family

ID=79553736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180054037.0A Active CN116096239B (zh) 2020-07-07 2021-07-06 治疗和预防生物膜的联合疗法

Country Status (7)

Country Link
US (1) US20230272054A1 (enExample)
EP (1) EP4178359A4 (enExample)
JP (2) JP2023533504A (enExample)
CN (1) CN116096239B (enExample)
AU (1) AU2021305167A1 (enExample)
CA (1) CA3183196A1 (enExample)
WO (1) WO2022010942A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120230733B (zh) * 2025-06-03 2025-07-29 山东三元生物科技股份有限公司 一种基于Spytag/SpyCatcher环化修饰的蔗糖磷酸化酶突变体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170178A1 (en) * 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2020072993A1 (en) * 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123396A1 (en) * 2010-03-29 2011-10-06 University Of Southern California Compositions and methods for the removal of biofilms
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
US20160340650A1 (en) * 2015-05-21 2016-11-24 Batu Biologics, Inc. Blood derived immune stimulatory compositions
EP3565589A1 (en) * 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
US20210139610A1 (en) * 2018-06-29 2021-05-13 Research Institute At Nationwide Children's Hospital Compositions and methods for mediating eps
LT3841120T (lt) * 2018-08-21 2025-11-10 Antikūnai, surišantys citrulinuotą histoną 2a ir (arba) 4
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
CA3145385A1 (en) * 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170178A1 (en) * 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2020072993A1 (en) * 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application

Also Published As

Publication number Publication date
JP2023533504A (ja) 2023-08-03
CA3183196A1 (en) 2022-01-13
EP4178359A2 (en) 2023-05-17
EP4178359A4 (en) 2024-10-09
WO2022010942A3 (en) 2022-03-24
WO2022010942A2 (en) 2022-01-13
US20230272054A1 (en) 2023-08-31
CN116096239A (zh) 2023-05-09
JP2026016462A (ja) 2026-02-03
AU2021305167A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP7593979B2 (ja) バイオフィルムの除去のためのペプチドおよび抗体
JP7627255B2 (ja) バイオフィルムを破壊するための抗体組成物
JP6351972B2 (ja) バイオフィルムの除去のための組成物および方法
US11690892B2 (en) HU specific interfering agents
US12419944B2 (en) DNABII vaccines and antibodies with enhanced activity
JP7661008B2 (ja) バイオフィルム関連障害の処置のための抗体断片
KR20210070331A (ko) 생물막 제거를 위한 hmgb1 단백질 유도체
JP2026016462A (ja) バイオフィルムの処置および予防のための併用療法
RU2851685C2 (ru) Композиции антител для разрушения биопленок
HK40111331A (en) Antibody compositions for disrupting biofilms

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant